Joint Formulary & PAD

Olanzapine - Mania

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
 

Status 2

Blue
Formulations :
  • Oro-dispersible tablets
Associated Icons :
R
SPC
Restrictions / Comments :
Important

Reserve orodispersible tablets for patients with swallowing difficulties or administration via a PEG tube

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Olanzapine
Indication :
Mania
Group Name :
Keywords :
Brand Names Include :
Important Information :

Initiation by a SABP specialist and stabilisation for a minimum of 3 months before any request to transfer prescribing responsibility.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2